Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.51

+2.7%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (2286)	12/12/2000 3:55:51 PM
From: IRWIN JAMES FRANKEL	Read Replies (1) of 52153

MAXM stub As Peter points out Maximine for HCV in combo with an interferon alpha looks promising. Maximine has three possible advantages in the HCV area that I see. 1) A replacement for ribavirin in combo treatment where the red cell suppression of ribavirin is an issue. 2) A possible third drug in Combo treatment of non-responders. 3) A tool for Roche in cracking the hold SGP has on US treatment of HCV (gained by bundled approval of IFNa and ribavirin). ij

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next